Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

525
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
525
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

765
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
765
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

452
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
452
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

774
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
774
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

600
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
600

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Catheter Ablation for Persistent Atrial Fibrillation.

The New England journal of medicine·2026
Same author

Patients' Perspectives on Personalized Glycemic Targets for Coronary Artery Disease Prevention Based on the Haptoglobin Phenotype: A Qualitative Study.

CJC open·2026
Same author

Haptoglobin, hemolysis, and renal vulnerability after pulsed field ablation: The hemoglobin-binding reserve.

Heart rhythm·2026
Same author

Prospective study of breakfast frequency and timing and risk of myocardial infarction and coronary artery disease in community-dwelling older adults: The Cardiovascular Health Study.

The journal of nutrition, health & aging·2026
Same author

Adherence to Different Dietary Patterns and Subsequent Risk of Total, Ischemic, and Hemorrhagic Stroke.

Stroke·2026
Same author

Assessing greenspace and cardiovascular disease risk through deep learning analysis of street-view imagery in the US-based nationwide Nurses' Health Study.

Environmental epidemiology (Philadelphia, Pa.)·2026
Same journal

Brain Iron in Nucleus Accumbens and Cognitive Function in Preeclampsia.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Hypertension Treatment Intentions: A Health Belief Model Analysis.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Changes in Retinal Microvasculature During Healthy Pregnancy Measured by AO.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Longitudinal Maternal IgG and IgA Glycosylation Profiles in Pregnancy Reveal Early Immune Alterations in Placenta-Related Complications: The Rotterdam Periconception Cohort.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Blood Pressure Variability and Outcomes Across Antihypertensive Regimens.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Rural Health and Health Disparities in Hypertension Management: A Scientific Statement From the American Heart Association.

Hypertension (Dallas, Tex. : 1979)·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K

Haptoglobin Phenotype and Cardiovascular Risk: The ACCORD Blood Pressure RCT.

Samantha K Lavallée1,2,3, Allie S Carew1,2,3, Rachel A Warren1,3

  • 1Department of Medicine (S.K.L., A.S.C., R.A.W., J.L,S., L.E.C.), Dalhousie University, Halifax, Nova Scotia, Canada.

Hypertension (Dallas, Tex. : 1979)
|November 11, 2025
PubMed
Summary
This summary is machine-generated.

Intensive blood pressure control reduced cardiovascular events in type 2 diabetes patients with Hp1 alleles but not Hp2-2. Haptoglobin phenotype may explain differing treatment responses in cardiovascular risk reduction.

Keywords:
blood pressurecardiovascular diseaseshaptoglobinshypertensionphenotype

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.2K

Related Experiment Videos

Last Updated: Jan 11, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.7K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.2K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Endocrinology

Background:

  • Hypertension is a known risk factor for cardiovascular disease (CVD), coronary artery disease (CAD), and stroke in type 2 diabetes.
  • Previous trials on intensive blood pressure control have yielded conflicting results regarding cardiovascular event reduction.
  • The haptoglobin (Hp) phenotype might be an unmeasured biological factor influencing these outcomes.

Purpose of the Study:

  • To investigate the association between intensive blood pressure control and cardiovascular events stratified by haptoglobin (Hp) phenotype.
  • To explore whether Hp phenotype influences the effectiveness of intensive blood pressure management in reducing cardiovascular risk in type 2 diabetes.

Main Methods:

  • Analysis of data from the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial.
  • Utilized multivariable-adjusted Cox proportional hazards regression models.
  • Stratified analysis comparing intensive versus standard blood pressure control in participants with the Hp2-2 phenotype and Hp1 allele carriers.

Main Results:

  • Intensive blood pressure therapy significantly lowered composite CVD risk in Hp1 allele carriers (HR, 0.76), but not in Hp2-2 phenotype participants (HR, 1.12).
  • A significant reduction in stroke risk was observed with intensive therapy in Hp1 carriers (HR, 0.53), but not in Hp2-2 participants.
  • No significant differences in CAD risk reduction were found between the groups with intensive versus standard therapy.

Conclusions:

  • The variable response to intensive blood pressure control observed in the ACCORD trial may be partly explained by differences in haptoglobin phenotypes.
  • Further research and replication are necessary to confirm the role of Hp phenotypes in modulating cardiovascular outcomes in type 2 diabetes.